Device/Diagnostics Quarterly Deal Statistics, Q3 2015
$1.4 billion in Q3 device financing was slightly lower than Q2's $1.8 billion with just one IPO versus Q2's seven. Acquisitions reached a high of $23 billion and diagnostics financing increased 30% over Q2 to $1 billion, while M&A activity at $1.2 billion showed a sharp decline from the previous quarter's $15.6 billion.
You may also be interested in...
Results from the CHAMPION study give St. Jude hope that its CardioMEMS system will stem the tide of heart failure.
After failing to tap into the consumer market six years ago with a health-information-oriented Personal Genomics Service, Illumina is taking a new tack in trying to leverage the value of its industry-leading gene sequencing platform – in this case setting its sights well beyond medicine and even wellness. Its new $100 million venture, Helix, also backed by two large investors, intends to become a massive “app store,” with partners creating content derived from consumers’ genomic information.
St. Jude Medical says it will pay $3.4 billion to own ventricular-assist device leader Thoratec, pointing to significant synergies in the heart failure and interventional cardiology markets. The deal would thrust VADs into a diversified cardiology firm for the first time, and it includes a "go-shop" period that leaves an opening for other big device firms to enter competing bids.